MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor and is currently in one Phase I combination clinical trial with Taxotere for solid tumors, two Phase I/II combination trials with Vidaza for hematological malignancies and with Gemzar for pancreatic cancer, and five Phase II clinical trials in hematological malignancies.